Weighing the Risks: Vivus View of Regulatory Risks in Qnexa Reprise
By
Cole Werble / Email the Author / The RPM Report November 2011, Vol. 8, No. 1
Street Smarts / Word Count: 1939 / Article # 2012500005
Executive Summary
A good-news press release from Vivus on the resubmission and acceptance of its application to FDA for the weight-loss drug Qnexa contains an unusually long and descriptive list of the risks involved in the application. This more than boiler-plate “forward-looking” statement adds new interest to the sport of footnote-analysis.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.